[A case report of a patient treatable by home palliative care, administered zoledronic acid used for bladder cancer with hypercalcemia].
We experienced a case in which zoledronate was effective for alleviating gastrointestinal symptoms arising from urinary bladder cancer-associated hypercalcemia, and long-term palliative home care was feasible by continuation of the administration. A female in her eighties was found to have bladder cancer. After transurethral resection of the bladder tumor, part of it was left unresected. Since dizziness, appetite loss, and general fatigue became severer, blood tests were carried out and hypercalcemia was observed. Then, zoledronate was administered and clinical symptoms quickly improved. After discussion with her and her family, palliative home care was selected. Home care was possible for about six months by continuation of zoledronate administration. In conclusion, it was suggested that careful continuous administration of zoledronate was also useful for symptom control in the palliative home care, and that it would potentially be a key drug for promotion of palliative home care.
Murakami
Nozomu
N
Palliative Care Team of Saiseikai Takaoka Hospital, Toyama Prefecture.
Tanabe
Kouichi
K
Murasugi
Keiko
K
Kadoya
Shinichi
S
Matsumoto
Yoko
Y
Yoshii
Ikuko
I
Fujikawa
Yasunaga
Y
Ohura
Fuyuhiro
F
D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006699:Home Care Services; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007093:Imidazoles / Q000627:therapeutic use*; D010166:Palliative Care; D013727:Terminal Care; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000628:therapy*; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid